Table 3. Patents on rheumatoid arthritis .
| Publication Number | Publication date | Assignee/Inventor | Patent Title | Reference |
| Patents On Nanosystems Approach in RA | ||||
| US20090232731A1 | 2009-09-17 | Medigene AG | “Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis” | 130 |
| US10709664B2 | 2020-07-14 | Yale University | “Nanolipogel comprising a polymeric matrix and a lipid shell” | 131 |
| US8715736B2 | 2014-05-06 | Florida Agricultural and Mechanical University FAMU | “Nanoparticle formulations for skin delivery” | 132 |
| AU2021106679A4 | 2021-12-02 | K. K. Sahu Shikha Shrivastava Deependra Singh Manju Rawat Singh |
Enzyme-loaded navigated nanomatrix systems to the inflamed synovial locus for the treatment of rheumatoid arthritis. | 133 |
| Patents related to other treatment approaches for RA | ||||
| US11195595B2 | 2021-12-07 | Scipher Medicine Corp. | “Method of treating a subject suffering from rheumatoid arthritis with anti-TNF therapy based on a trained machine learning classifier.” | 134 |
| US20170157249A1 | 2017-06-08 | AbbVie Biotechnology Ltd | “Uses and compositions for treatment of rheumatoid arthritis” | 135 |
| US20210230719A1 | 2021-07-29 | Sanofi Biotechnology SAS Regeneron Pharmaceuticals Inc |
“Compositions for the treatment of rheumatoid arthritis and methods of using same” | 136 |
| US10913792B2 | 2021-02-09 | Morphosys AG | “Treatment for rheumatoid arthritis.” | 137 |
| EP3102575B1 | 2021-01-13 | Galapagos NV | “Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders.” | 138 |
| EP2680884B1 | 2018-01-17 | F Hoffmann La Roche AG | “Biological markers and methods for predicting response to b-cell antagonists.” | 139 |
| CN102597268B | 2017-09-22 | F Hoffmann La Roche AG | “For a treat, diagnose and monitoring rheumatoid arthritis method” | 140 |
| CA2760460C | 2019-04-02 | Zynerba Pharmaceuticals Inc | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same. | 141 |
| AU2018260845B2 | 2020-09-03 | Takeda Pharmaceutical Co Ltd | “Evaluation and treatment of bradykinin-mediated disorders” | 142 |